Pfizer raises sales forecast for Covid vaccine by almost a third to $33 bn

Pfizer Inc. now expects its Covid-19 vaccine to bring in $33.5 billion in revenue this year, putting it on course to become one of the best-selling medicines of all time.
 

The New York drugmaker had previously projected vaccine sales for the year of $26 billion. The upward revision is a sign demand for the shots, which Pfizer sells with German partner BioNTech SE, is surging as countries battle new outbreaks fueled by the delta virus variant.

In the second quarter, the vaccine booked $7.8 billion in sales, Pfizer said in a statement Wednesday, more than the $7.05 billion analysts expected,